157 related articles for article (PubMed ID: 37173322)
1. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.
Sargas C; Ayala R; Larráyoz MJ; Chillón MC; Rodriguez-Arboli E; Bilbao C; Prados de la Torre E; Martínez-Cuadrón D; Rodríguez-Veiga R; Boluda B; Gil C; Bernal T; Bergua J; Algarra L; Tormo M; Martínez-Sánchez P; Soria E; Serrano J; Alonso-Dominguez JM; García R; Amigo ML; Herrera-Puente P; Sayas MJ; Lavilla-Rubira E; Martínez-López J; Calasanz MJ; García-Sanz R; Pérez-Simón JA; Gómez Casares MT; Sánchez-García J; Barragán E; Montesinos P;
Blood Cancer J; 2023 May; 13(1):77. PubMed ID: 37173322
[TBL] [Abstract][Full Text] [Related]
2. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
[TBL] [Abstract][Full Text] [Related]
3. Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.
Chen E; Jiao C; Yu J; Gong Y; Jin D; Ma X; Cui J; Wu Z; Zhou J; Wang H; Su B; Ge J
Cancer Med; 2023 Dec; 12(24):21615-21626. PubMed ID: 38098254
[TBL] [Abstract][Full Text] [Related]
4. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
[TBL] [Abstract][Full Text] [Related]
5. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
Mrózek K; Kohlschmidt J; Blachly JS; Nicolet D; Carroll AJ; Archer KJ; Mims AS; Larkin KT; Orwick S; Oakes CC; Kolitz JE; Powell BL; Blum WG; Marcucci G; Baer MR; Uy GL; Stock W; Byrd JC; Eisfeld AK
Leukemia; 2023 Apr; 37(4):788-798. PubMed ID: 36823396
[TBL] [Abstract][Full Text] [Related]
6. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Herold T; Rothenberg-Thurley M; Grunwald VV; Janke H; Goerlich D; Sauerland MC; Konstandin NP; Dufour A; Schneider S; Neusser M; Ksienzyk B; Greif PA; Subklewe M; Faldum A; Bohlander SK; Braess J; Wörmann B; Krug U; Berdel WE; Hiddemann W; Spiekermann K; Metzeler KH
Leukemia; 2020 Dec; 34(12):3161-3172. PubMed ID: 32231256
[TBL] [Abstract][Full Text] [Related]
7. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Rausch C; Rothenberg-Thurley M; Dufour A; Schneider S; Gittinger H; Sauerland C; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; von Bergwelt-Baildon M; Spiekermann K; Herold T; Metzeler KH
Leukemia; 2023 Jun; 37(6):1234-1244. PubMed ID: 37041198
[TBL] [Abstract][Full Text] [Related]
8. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.
Harada Y; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kobayashi S; Kitamura K; Sakaida E; Onizuka M; Takeshita A; Ishida F; Suzushima H; Ishizawa K; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Leuk Res; 2018 Mar; 66():20-27. PubMed ID: 29360622
[TBL] [Abstract][Full Text] [Related]
9. Real-world genomic profiling of acute myeloid leukemia and the impact of European LeukemiaNet risk stratification 2022 update.
da Rosa SEA; de Lima LB; Silveira CN; Cortes LGF; de Oliveira Filho JB; de Souza Reis R; Cervato MC; Rodrigues PHS; de Oliveira Pelegrino K; Petroni RC; da Silva Araujo E; Campregher PV
Clin Transl Oncol; 2023 Dec; 25(12):3431-3436. PubMed ID: 37165281
[TBL] [Abstract][Full Text] [Related]
10. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
Eisfeld AK; Kohlschmidt J; Mims A; Nicolet D; Walker CJ; Blachly JS; Carroll AJ; Papaioannou D; Kolitz JE; Powell BE; Stone RM; de la Chapelle A; Byrd JC; Mrózek K; Bloomfield CD
Leukemia; 2020 Dec; 34(12):3215-3227. PubMed ID: 32461631
[TBL] [Abstract][Full Text] [Related]
11. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Döhner K; Thiede C; Jahn N; Panina E; Gambietz A; Larson RA; Prior TW; Marcucci G; Jones D; Krauter J; Heuser M; Voso MT; Ottone T; Nomdedeu JF; Mandrekar SJ; Klisovic RB; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Jansen JH; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Benner A; Pallaud C; Stone RM; Döhner H; Bloomfield CD
Blood; 2020 Jan; 135(5):371-380. PubMed ID: 31826241
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
Mrózek K; Marcucci G; Nicolet D; Maharry KS; Becker H; Whitman SP; Metzeler KH; Schwind S; Wu YZ; Kohlschmidt J; Pettenati MJ; Heerema NA; Block AW; Patil SR; Baer MR; Kolitz JE; Moore JO; Carroll AJ; Stone RM; Larson RA; Bloomfield CD
J Clin Oncol; 2012 Dec; 30(36):4515-23. PubMed ID: 22987078
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine.
Kim M; Ahn SY; Kim T; Jung SH; Song GY; Yang DH; Lee JJ; Kim MY; Park JH; Shin MG; Ahn JS; Kim HJ; Kim DDH
Hematology; 2024 Dec; 29(1):2324417. PubMed ID: 38433437
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal Abnormalities and Prognosis in
Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
[TBL] [Abstract][Full Text] [Related]
15. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
16. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.
Lachowiez CA; Long N; Saultz J; Gandhi A; Newell LF; Hayes-Lattin B; Maziarz RT; Leonard J; Bottomly D; McWeeney S; Dunlap J; Press R; Meyers G; Swords R; Cook RJ; Tyner JW; Druker BJ; Traer E
Blood Adv; 2023 May; 7(9):1899-1909. PubMed ID: 36441905
[TBL] [Abstract][Full Text] [Related]
17. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Bataller A; Garrido A; Guijarro F; Oñate G; Diaz-Beyá M; Arnan M; Tormo M; Vives S; de Llano MPQ; Coll R; Gallardo D; Vall-Llovera F; Escoda L; Garcia-Guiñon A; Salamero O; Sampol A; Merchan BM; Bargay J; Castaño-Díez S; Esteban D; Oliver-Caldés A; Rivero A; Mozas P; López-Guerra M; Pratcorona M; Zamora L; Costa D; Rozman M; Nomdedéu JF; Colomer D; Brunet S; Sierra J; Esteve J
Blood Adv; 2022 Feb; 6(4):1193-1206. PubMed ID: 34911079
[TBL] [Abstract][Full Text] [Related]
18. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
19. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
Oran B; Jimenez AM; De Lima M; Popat UR; Bassett R; Andersson B; Borthakur G; Bashir Q; Chen J; Ciurea SO; Jabbour E; Cortes J; Kebriaei P; Khouri IF; Qazilbash MH; Ravandi F; Rondon G; Lu X; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1405-1412. PubMed ID: 25840338
[TBL] [Abstract][Full Text] [Related]
20. Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.
Oñate G; Pratcorona M; Garrido A; Artigas-Baleri A; Bataller A; Tormo M; Arnan M; Vives S; Coll R; Salamero O; Vall-Llovera F; Sampol A; Garcia A; Cervera M; Avila SG; Bargay J; Ortín X; Nomdedéu JF; Esteve J; Sierra J;
Blood Cancer J; 2023 May; 13(1):69. PubMed ID: 37147301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
